AstraZeneca Lifted By Tagrisso Combo Lung Cancer Data

Shows Improvement Over Monotherapy

Data from the FLAURA2 trial suggest AstraZeneca could soon be able to expand use of Tagrisso in the first-line setting, widening the gap over Johnson & Johnson’s Rybrevant.

Sodertalje, Sweden - April 27, 2014: Three purple flags with the logo for Atrazeneca flying in the wind on top of the flagpoles against the blue sky.
• Source: AstraZeneca

AstraZeneca PLC's aim of securing the market-leading position of its biggest seller Tagrisso has received a major boost with the release of late-stage data demonstrating the additional benefit of combining the drug with chemotherapy for lung cancer patients.

The UK major has announced positive high-level results from the FLAURA2 Phase III trial which showed that Tagrisso (osimertinib) in...

More from Anticancer

More from Therapy Areas

ProKidney Pins Hopes On Accelerated Approval For Rilparencel

 

After posting encouraging Phase II results, the company plans to meet with the US FDA about using data from an ongoing Phase III study for an accelerated approval.

Merck & Co.’s Verona Acquisition Marks A Return To Respiratory

 

With the $10bn acquisition of Verona, Merck gains the marketed COPD drug Ohtuvayre, reentering respiratory, where it was once a leader with Singulair.

Lilly’s Kisunla Label Update Lowers ARIA-E Risk For Alzheimer’s Patients

 
• By 

The updated US FDA label modifies dose titration based on TRAILBLAZER-ALZ 6, a study that showed a more gradual rise in dosing levels reduced ARIA-E incidence without reducing amyloid clearance.